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Objectives. This study was undertaken to better understand the
functional and prognostic significance of silent relative to symp-
tomatic ischemia.
Background. Previous studies have reached conflicting conclu-
sions as to whether painless ischemia identified during noninva-
sive cardiac testing is related to a lesser extent of myocardial
ischemia or a different prognosis than ischemia accompanied by
angina, or both.
Methods. Nine hundred thirty-six clinically stable patients 1 to
6 months after an acute coronary event, either myocardial infarc-
tion or unstable angina, underwent ambulatory monitoring, exer-
cise treadmill testing and stress thallium-201 scintigraphy. They
were then followed up prospectively for a mean of 23 months for
recurrent cardiac events (cardiac death, nonfatal myocardial
infarction or unstable angina).
Results. Compared with patients with symptomatic ischemia
during testing (n 5 125), those with silent ischemia (n 5 378)
demonstrated less severe and extensive reversible defects on
stress thallium scintigraphy (p 5 0.0008), less functional impair-
ment during treadmill testing manifested by longer exercise
duration (640 6 173 vs. 529 6 190 s, p 5 0.002) and longer time
to ST segment depression (530 6 215 vs. 419 6 205 s, p 5 0.0001)
and less frequent ST segment depression during ambulatory
monitoring (9% vs. 19%, p 5 0.005). Patients with symptomatic
ischemia had a significantly (p 5 0.004) increased number of
subsequent recurrent cardiac events (28.8%) versus those with
silent (18.0%) or no (17.3%) ischemia. Adverse outcomes were
especially concentrated in the subgroup with symptomatic isch-
emia and poor exercise tolerance. The difference in cardiac event
rates between patients with silent versus symptomatic ischemia
persisted after adjustment for baseline clinical characteristics by
Cox regression analysis.
Conclusions. Patients with painless ischemia during exercise
testing 1 to 6 months after recovery from a coronary event have
less jeopardized ischemic myocardium and fewer recurrent car-
diac events than patients with symptomatic ischemia.
(J Am Coll Cardiol 1997;29:756–63)
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Several important issues regarding the pathophysiologic mech-
anism and clinical significance of silent ischemia remain unre-
solved. First, it is unclear why myocardial ischemia tends to be
predominantly symptomatic in some patients but silent in
others. Proposed explanations have included intraindividual
differences in somatic pain tolerance (1,2), differences in
psychologic and cultural background (3–5) and differences in
central modulation of incoming pain signals (6). Several inves-
tigators (7–13), using a variety of techniques to assess myocar-
dial perfusion, have reached conflicting conclusions as to
whether silent ischemia differs from symptomatic ischemia as a
result of corresponding differences in the severity and extent of
the underlying myocardial ischemic insult.
A second unresolved issue relates to the prognostic rele-
vance of silent ischemia detected during noninvasive testing.
Again, previous studies have led to contradictory conclusions
as to whether future cardiac events are less (14,15), equally
(9,11,16–20) or more (21,22) likely in patients who demon-
strate silent as opposed to symptomatic ischemia during stress
testing. However, despite the myriad of studies that have
addressed the issue of prognosis, almost all have been retro-
spective in design, and many have lacked the statistical power
necessary to detect a potential difference in cardiac event rates.
With the current analysis of a prospectively designed study, we
had the opportunity to investigate the mechanisms, clinical
correlates and prognostic significance of silent and symptom-
atic myocardial ischemia in patients who had recently recov-
ered from a documented coronary event.
Methods
Patient recruitment. The present study involved 936 pa-
tients from 12 centers in the United States, Canada and Israel
who were participants in the Multicenter Study of Myocardial
Ischemia (MSMI). Full details and major results of this study
have been published previously (23) (see Appendix). Enroll-
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ment began on July 1, 1988 and ended on May 31, 1991, with
follow-up through November 30, 1991. All patients admitted to
the coronary care unit with documented myocardial infarction
or unstable angina were considered for enrollment. Confirma-
tion of enzyme level elevation was necessary for the diagnosis
of acute myocardial infarction. The diagnosis of unstable
angina required an increase in the frequency or duration of
typical anginal symptoms plus transient ischemic-type ST or T
wave electrocardiographic (ECG) changes without enzyme
level elevation indicative of infarction.
Patients were scheduled for enrollment into the study 1 to
6 months (mean [6SD] 2.7 6 1.4) after their index coronary
event, at a time when they were considered to be clinically
stable. Patients were ineligible for enrollment for any of the
following prespecified reasons: coronary artery bypass graft
surgery after the index coronary event, coronary angioplasty
performed ,1 month before enrollment, major medical co-
morbidity, musculoskeletal disorders that would prevent the
patient from performing the exercise test, use of cardiac
glycosides, bundle branch block or atrial fibrillation, implanted
pacemaker, participation in other investigational studies, psy-
chological factors, or physician refusal.
Of the 2,096 patients who met the eligibility requirements,
informed consent was obtained from 936. Nonenrollment of
eligible patients was due to a variety of reasons, including
patient or physician refusal, unanticipated interim medical
problems, vacation, inability to contact eligible patients within
the 6-month time window and miscellaneous logistic problems.
At the time of enrollment, a complete medical history was
recorded, and baseline noninvasive testing for myocardial
ischemia was obtained, consisting of a 12-lead rest ECG, 24-h
ambulatory ECG and exercise tolerance test with thallium-201
scintigraphy. Anti-ischemic medications were withheld only on
the morning of the exercise test.
Data acquisition. Details for the performance and evalua-
tion of the noninvasive ischemic tests were described in full in
the primary publication (23). Treadmill exercise testing was
performed using a slightly modified Bruce protocol beginning
with a 3-min “stage 1⁄2,” 1.7-mph at 5% grade. Exercise was
terminated when one of the following end points was reached:
target heart rate, severe fatigue, severe angina, hypotension or
ventricular tachycardia. Patients who experienced angina dur-
ing the exercise test were identified. At peak exercise, 2.5 mCi
of thallium-201 was injected intravenously, and planar myocar-
dial imaging was started within 5 min. Delayed imaging was
performed 2.5 to 3 h later. Two-channel ambulatory ECGs
were obtained on Marquette model 8500 series cassette tape
recorders (Marquette Electronics, Inc.), with positive elec-
trodes placed in the CM3 and CM5 positions. Coronary
angiography was performed (as a nonprotocol procedure) in
786 patients (84%) before or during the study period. Angio-
graphic results are reported in terms of the 75% coronary
artery jeopardy score (24).
Core laboratories. Core laboratories were established to
maximize consistency of interpretation and coding of the
noninvasive ischemic tests used in the MSMI trial.
An ischemic-type ST segment abnormality on exercise
testing was defined as horizontal or downsloping ST segment
depression .0.1 mV below the preexercise ST segment posi-
tion in any lead during or after exercise. Interpretation of each
thallium-201 study was based on analysis of quantitative cir-
cumferential profiles with visual overreads, as previously de-
scribed (25). The studies were categorized as normal or as
having reversible (ischemia) or fixed defects (scar). Four-level
ordinal grading reflecting the extent and severity of reversible
defects (none, mild, moderate, severe) was also performed
(26). ST segment shifts or reversible defects temporally asso-
ciated with angina were considered to reflect symptomatic
ischemia, whereas those occurring without symptoms were
deemed to show silent ischemia. An ischemic-type ST segment
abnormality on the ambulatory ECG was defined as .0.1-mV
ST segment depression below the baseline ST segment posi-
tion that persisted for at least 1 min.
All 936 patients were subclassified into three groups on the
basis of the combined results of the exercise ECG and thallium
scintigram: 1) symptomatic group 5 angina during exercise and
objective ischemia on either test (n5 125); 2) silent group5 no
angina during exercise but ischemia on one or both tests (n 5
378); and 3) no-ischemia group 5 patients without ischemia on
either test (n 5 433) (Table 1).
Follow-up. Patients were contacted at 4-month intervals
throughout the study to determine their clinical status, phar-
macologic and interventional therapy and the occurrence of
study end points. All patients were followed up for at least 6
months, to a maximum of 43 months. The mean duration of
follow-up was 23 months.
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
MSMI 5 Multicenter Study of Myocardial Ischemia
Table 1. Results of Baseline Tests
Test
Ischemia [no. (%) of pts]
Total No.
of PtsNone Silent Symptomatic
ETT 650 (71%) 190 (21%) 76 (8%) 916
STS 526 (59%) 270 (30%) 98 (11%) 894
ETT or STS 433 (46%) 378 (40%) 125 (13%) 936
ETT 5 exercise treadmill test; pts 5 patients; STS 5 stress thallium scintigraphy.
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End points. The prespecified end points were death due to
cardiac cause, nonfatal myocardial infarction and unstable
angina occurring on or before November 30, 1991. The criteria
for diagnosing nonfatal myocardial infarction were the same as
those applied to the index coronary event. The diagnosis of
unstable angina required hospital admission to a coronary care
unit for the increase in the frequency or duration of typical
anginal symptoms and either ischemic-type ST segment or T
wave ECG changes or an increase in antianginal therapy, or
both, but without enzyme level elevation indicative of infarc-
tion. Cardiac events were enumerated as follows: 1) the primary
end point (cardiac death, nonfatal infarction myocardial in-
farction or unstable angina, whichever occurred first); 2) a
restricted secondary end point (myocardial infarction or car-
diac death); and 3) cardiac death.
Statistical analysis. Descriptive statistics are expressed in
terms of mean value 6 SD. All results are reported with the
use of two-tailed p values. Sample size calculations for the
MSMI trial were previously described (23). Baseline clinical
characteristics and ischemic test variables of patients with
silent and symptomatic ischemia were compared using chi-
square tests (for dichotomous variables) or t and F tests (for
continuous variables). Multivariate models using type of isch-
emia (silent or symptomatic) as the outcome variable were
created to test for independence of univariate relations be-
tween covariates and silent and symptomatic ischemia (SAS
statistical software) (27). The first model used the 12 prese-
lected clinical and 2 medication covariates listed in Table 2. A
backward selection approach was used by which variables were
omitted one at a time until all variables had a p value ,0.10.
Using the same approach, a second model was created for the
exercise and thallium test variables shown in Table 3.
The effects of silent, symptomatic and no ischemia on time
to end point were examined graphically by Kaplan-Meier
curves (28); the log-rank statistic was used when comparing the
two curves. Multivariate end-point analysis was performed
using the Cox proportional hazards regression model (29) for
cardiac-related end points (SAS statistical software). Patients
who died of noncardiac causes were censored at the time of
death. A backward selection procedure was used to identify
important risk predictors for the time to end point from the 12
preselected clinical covariates shown in Table 2, with geo-
graphic region (North America or Israel) entered as a strati-
fication factor. A p value $0.10 was used for removing a
variable in constructing the basic clinical model. The contribu-
tion of type of ischemia (silent or symptomatic) was then
evaluated. Only “nominal” confidence levels and p values are
reported for further subgroup analysis.
Results
Clinical characteristics. Exercise treadmill testing and
thallium scintigraphy were performed at enrollment an aver-
age of 2.7 6 1.4 months after the acute index coronary event.
Of the 936 patients who underwent testing, 503 demonstrated
objective evidence of ischemia on at least one of these two tests
(Table 1). Ischemia was clinically silent in 378 patients (75%)
and was accompanied by angina in 125 (25%).
Table 2. Baseline Clinical Characteristics
Ischemia on Noninvasive Testing
3-Tailed
p Values*
None (%)
(n 5 433)
Silent (%)
(n 5 378)
Symptomatic (%)
(n 5 125)
Mean age (yr) 57.3 58.8 59.5 0.03
Female 31 18 18 , 0.001
Event type
Q wave MI 42 49 35 0.01
Non-Q wave MI 26 25 26
Unstable angina 32 26 39 0.01
Thrombolytic therapy
for index event
32 34 19 , 0.01
CHF at index event 16 17 15
Previous MI 14 22 30 , 0.001
Angina in past mo 31 25 54 , 0.001
Diabetes (taking
insulin)
5 6 7
Hypertension 41 40 46
Smoking at baseline 15 12 12
PTCA during index
hospital period
39 28 27 , 0.01
Beta-blocker therapy 47 54 56
Calcium channel
blocker therapy
60 48 63 0.001
*Only significant p values (,0.05) are shown. CHF 5 congestive heart failure; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty.
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Clinical characteristics of patients with no ischemia, silent
ischemia and symptomatic ischemia are shown in Table 2.
Patients in the silent ischemia group were more likely (p 5
0.01) to have experienced a Q wave myocardial infarction as
their index event (49% vs. 35%) and to have received throm-
bolytic therapy (34% vs. 19%) than patients in the symptom-
atic ischemia group. Patients in the silent ischemia group were
less likely (p 5 0.01) to have unstable angina as their index
event (26% vs. 39%) than the symptomatic patients. At
baseline evaluation, patients with silent ischemia were less
likely (p , 0.001) to have experienced angina in the preceding
month (25% vs. 54%) and were less likely (p , 0.001) to have
been prescribed calcium channel blocking agents (48 vs. 63%).
The silent and symptomatic groups were similar with respect to
age, gender, diabetes, smoking, hypertension, history of myo-
cardial infarction before the index coronary event or incidence
of coronary angioplasty during the index hospital period
(Table 2). Multivariate logistic regression modeling confirmed
that, independent of other clinical characteristics, patients who
experienced silent ischemia during testing were less likely to
have experienced clinical angina in the preceding month (p 5
0.001), less likely to have been prescribed calcium channel
blockers (p 5 0.03) and more likely to have received throm-
bolytic therapy during the index hospital period than patients
with symptomatic ischemia (p 5 0.002).
Relative to those with no ischemia on exercise testing,
patients with silent ischemia were older and more often male,
more often had a previous myocardial infarction and less often
underwent coronary angioplasty during the index hospital
period or recent clinical angina (Table 2).
Extent of myocardial ischemia. In an attempt to assess
differences in severity and extent of ischemia between patients
with silent and symptomatic ischemia, diagnostic test data were
examined in detail (Table 3). Patients who experienced silent
ischemia had a longer time to 1-mm ST segment depression
during exercise testing (530 6 215 vs. 420 6 205 s, p 5 0.001),
greater total exercise duration (640 6 173 vs. 529 6 190 s, p ,
0.001), less extensive reversible defects on thallium scintigra-
phy (51% vs. 63% with moderate or severe scintigraphic
ischemia, p 5 0.04) and a lower likelihood of demonstrating
1-mm ST segment depression during ambulatory electrocardi-
ography (9% vs. 19%, p 5 0.005) than patients with symptom-
atic ischemia. Achievement of target heart rate was the reason
for terminating the exercise test more often in patients with
silent ischemia (14% vs. 6%, p 5 0.03).
Multivariate logistic regression analysis was performed uti-
lizing the thallium and exercise test variables shown in Table 3.
Silent myocardial ischemia remained independently related to
less severe/extensive ischemia on thallium scintigraphy (p 5
0.0008), longer time to 1-mm ST segment depression (p 5
0.002) and longer total exercise duration (p 5 0.0001).
End points. Kaplan-Meier analysis was performed to de-
termine the univariate relation between silent, symptomatic
and no exercise-induced ischemia and time to the predefined
cardiac end points. Patients who developed symptomatic myo-
cardial ischemia during baseline testing were significantly more
likely to experience a primary end point (cardiac death,
nonfatal myocardial infarction or unstable angina) during the
23-month follow-up period than patients who developed silent
or no ischemia (p 5 0.004) (Fig. 1). The incidence of primary
end points did not differ significantly between patients with
silent ischemia and no inducible ischemia.
The incidence of restricted end points (nonfatal infarction
or cardiac death) did not differ significantly as a function of
symptoms during testing (Fig. 2). However, cardiac death by
itself was significantly more common in patients with symp-
tomatic ischemia than those with silent or no ischemia (p 5
0.001) (Fig. 3). Although revascularization procedures were
Table 3. Diagnostic Test Results
Ischemia on Noninvasive Testing p Value
None
(n 5 433)
Silent
(n 5 378)
Symptomatic
(n 5 125) 3-Tailed
Silent vs.
Symptomatic
ETT
Exercise duration (s) 6166 198 640 6 173 529 6 190 , 0.001 , 0.001
Time to 1-mm ST segment
depression (s)
NA 530 6 215 420 6 205 NA , 0.001
STS
Ischemia , 0.001 0.04
None (%) 100 30 21
Mild (%) 0 19 16
Moderate (%) 0 21 21
Severe (%) 0 30 42
Scar (%) 41 55 57 , 0.001 NS*
Ischemia on ambulatory ECG (%) 4 9 19 , 0.001 , 0.005
Mean 75% coronary angiographic
jeopardy score
3.1 3.8 4.2 , 0.001 , 0.05
*p . 0.05. Data presented are mean value 6 SD, unless otherwise indicated. ECG 5 electrocardiogram; NA 5 not
applicable; other abbreviations as in Table 1.
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not a prespecified study end point, patients in the silent
ischemia group were significantly less likely than those in the
symptomatic group to undergo coronary angioplasty or bypass
surgery during the follow-up period (21% vs. 30%, p 5 0.04).
Cox regression analysis was performed to test whether the
presence or absence of symptoms during baseline testing
served as an independent predictor of prognosis apart from
that of other baseline clinical variables listed in Table 1.
Clinical variables independently associated (p , 0.10) with the
occurrence of a primary end-point included angina in the
month preceding baseline testing, diabetes, hypertension, pre-
vious myocardial infarction and coronary angioplasty per-
formed during the index hospital period but before baseline
testing (Table 4). After adjusting for these covariates, the
additional presence of silent ischemia during baseline cardiac
testing did not make a significant independent contribution to
the model (p5 0.82), whereas symptomatic ischemia remained
a significant independent predictor of recurrent cardiac events
(p 5 0.036). Likewise, when Cox analysis was restricted to
consider only cardiac death, the presence of symptomatic
ischemia during baseline testing emerged as a strong indepen-
dent predictor of cardiac mortality (Table 4). Further analysis
incorporating variables related to exercise time and time to ST
segment depression during treadmill testing revealed that the
increased risk associated with symptomatic ischemia appeared
to be concentrated in the subgroup with a short (,6 min)
exercise duration. In patients with symptomatic ischemia and
exercise duration ,6 min, the hazard ratio was 1.9 (“nominal”
Figure 1. Kaplan-Meier analysis for time to recurrent cardiac event
(cardiac death, nonfatal myocardial infarction, unstable angina) ac-
cording to presence and type of ischemia (symptomatic, silent or
none).
Figure 2. Kaplan-Meier analysis for time to restricted secondary
cardiac events (cardiac death or nonfatal myocardial infarction) ac-
cording to presence and type of ischemia (symptomatic, silent or
none).
Figure 3. Kaplan-Meier analysis for time to cardiac death according to
type of ischemia (symptomatic, silent or none).
Table 4. Clinical Variables Associated With Cardiac End Points*
End Point HR (95% CI) p Value
Primary
Angina in previous mo 1.76 (1.30–2.40) , 0.001
Diabetes 2.29 (1.41–3.71) 0.001
Hypertension 1.39 (1.03–1.87) , 0.03
Previous MI 1.38 (0.98–1.93) 0.06
PTCA during index hospital period 1.39 (1.01–1.91) 0.05
Ischemia
Silent 1.04 (0.74–1.45) 0.82
Symptomatic 1.55 (1.03–2.33) 0.04
Cardiac death
Older age† 1.48 (0.95–2.29) 0.08
Prior MI 2.23 (0.94–5.26) 0.07
Ischemia
Silent 2.35 (0.73–7.55) 0.15
Symptomatic 5.06 (1.49–17.1) 0.009
*Final Cox proportional hazards model, including all significant clinical
predictors for the primary end point (cardiac death, nonfatal myocardial
infarction [MI], unstable angina) and type of ischemia during testing (silent or
symptomatic). †Per decades away from age 60 years; thus, the risk of death is
estimated to be 48% higher in patients 70 years old than in those 60 years old.
CI 5 confidence interval; HR 5 hazard ratio; PTCA 5 percutaneous translu-
minal coronary angioplasty.
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95% confidence interval [CI] 1.2 to 2.8, “nominal” p 5 0.003)
for the primary end point and 3.8 (nominal 95% CI 1.5 to 9.4,
nominal p 5 0.005) for cardiac death, whereas no significant
increase in risk remained apparent in other groups regardless
of occurrence of symptoms.
Discussion
The purpose of the present study was twofold: 1) to
determine whether the presence or absence of exercise-
induced ischemic symptoms is related to the severity and
extent of the underlying myocardial ischemia; and 2) to
determine the prognostic importance of silent myocardial
ischemia relative to symptomatic ischemia in a large cohort of
prospectively evaluated patients with clinically stable coronary
disease. Our results demonstrate that patients who experience
silent myocardial ischemia during noninvasive testing have
significantly smaller amounts of jeopardized ischemic myocar-
dium, as determined by thallium scintigraphy, than patients
who develop symptomatic ischemia. Likewise, ECG signs of
ischemia appeared later in the exercise period, and exercise
duration was greater, in the silent ischemia group. Patients
with silent ischemia were also significantly less likely to expe-
rience a recurrent spontaneous cardiac event. Cox regression
analysis demonstrated that this difference in cardiac event
rates between patients with silent ischemia and symptomatic
ischemia persisted even after adjustment for other baseline
clinical characteristics associated with poor outcome. The
combination of symptomatic ischemia and poor exercise toler-
ance was a very powerful predictor of adverse events.
Pathophysiologic mechanisms of silent ischemia. From a
pathophysiologic standpoint, it remains unclear precisely why
some patients experience symptoms in conjunction with objec-
tive evidence of ischemia during stress testing, whereas other
patients (or the same patient at other times) manifest ischemia
that is clinically silent. Previous studies have suggested that
patients who develop silent ischemia during diagnostic testing
may differ from those who develop symptoms in terms of
psychologic and personality traits (3,4), ethnocultural factors
(5), general ability to tolerate painful stimuli (1,2) and ability
to centrally modulate incoming pain signals (6).
Several investigators (7–13), using exercise ECG, radionu-
clide angiographic and thallium scintigraphic variables, have
attempted to determine whether the development of anginal
symptoms is related to the extent of underlying myocardial
ischemia. Bonow et al. (16), in a study that included 131
patients with angiographically documented coronary disease,
found that patients with silent ischemia during exercise radio-
nuclide angiography were significantly less likely to demon-
strate a decrease in left ventricular ejection fraction with
exercise than patients who developed angina during testing.
Likewise, Travin et al. (11), using a case-control approach,
found that patients with silent ischemia on exercise thallium
scintigraphy had less frequent and severe ischemic ST depres-
sion and less extensive and severe defects on thallium imaging.
However, these results are in disagreement with studies report-
ing no significant differences in severity or extent of thallium
scintigraphic changes between patients who experienced silent
as opposed to symptomatic ischemia (8–10).
Several potential explanations exist for the discrepant find-
ings of these earlier reports. As elegantly demonstrated by
Klein et al. (13), previous studies have been conducted using
widely different patient populations, ranging from clinically
asymptomatic subjects to only those with evidence of a marked
ischemic response to exercise. Previous studies have also used
differing definitions of silent ischemia, and few have used
multivariate analysis. Within our study cohort, which consisted
uniformly of clinically stable patients with known coronary
disease, silent myocardial ischemia was independently associ-
ated with thallium scintigraphic and exercise ECG findings
suggestive of smaller amounts of jeopardized ischemic myo-
cardium. This association supports the concept that the symp-
tomatic appreciation of pain reflects a greater extent and
severity of the induced myocardial ischemia than myocardial
ischemia that does not yield symptoms.
Silent ischemia and prognosis. The prognostic importance
of silent ischemia relative to symptomatic ischemia during
noninvasive testing also remains controversial. Cole and
Ellestad (14), in a retrospective analysis of 1,402 patients who
had ECG evidence of ischemia during treadmill testing, found
that coronary events (cardiac death, myocardial infarction or
progression of angina) were two times more frequent in
patients with symptomatic ischemia as opposed to silent isch-
emia. Mark et al. (15), in reviewing the 5-year outcome of 842
consecutive patients in the Duke Cardiovascular Database who
had angiographically documented coronary disease and an
abnormal exercise test result, found that patients with silent
ischemia during exercise had significantly better overall sur-
vival and infarct-free survival rates. However, several investi-
gators (9,11,16–20) failed to discover any prognostic differ-
ences in patients with ischemic responses to exercise on the
basis of the presence or absence of coexistent angina. Callahan
et al. (19), in the largest of the negative studies, found no
mortality difference at 2 years based on development of angina
during exercise in a retrospective study of 1,773 veterans
referred for treadmill testing. Rounding out the controversy,
two retrospective studies (21,22) describe an increased risk of
subsequent cardiac events in patients with silent ischemia as
opposed to symptomatic ischemia during cardiac stress testing.
These widely discordant findings most likely result from
factors related to study design. Most important, few of the
previous studies focusing on prognosis have used prospective
follow-up. In addition, many of the prognostic studies have
lacked adequate statistical power to detect potential differ-
ences between patients with silent and symptomatic ischemia.
Previous studies have included patient groups at differing risks
for cardiac events and have used a variety of end points (e.g.,
death from any cause; spontaneous cardiac end points only;
spontaneous cardiac end points plus revascularization). Defi-
nitions of silent ischemia have also varied from study to study.
Furthermore, most investigations have not included multivar-
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iate or Cox analysis to assess the independence of the observed
relation between silent myocardial ischemia and outcome.
With the current study, we had the opportunity to overcome
many of these methodologic problems. The study was prospec-
tive in design; the cohort studied was large, with well defined
entry and exclusion criteria; end point analysis was based on
the occurrence of carefully documented spontaneous cardiac
events; and multivariate and Cox regression analysis were
used.
The primary results of the MSMI trial (23) demonstrated
that detection of ischemia by noninvasive testing in a large
group of clinically stable patients 1 to 6 months after recovery
from an acute coronary event had no significant independent
prognostic value in predicting subsequent coronary events.
Increased risk for primary cardiac events was evident only in
small, selected patient subsets (exercise-induced ST segment
depression with limited exercise duration or reversible thallium
defect plus increased lung uptake). Although the present
substudy serves to identify an association between symptomatic
ischemia and recurrent events, it does not alter the general
conclusions reached in the primary study regarding the overall
utility of noninvasive testing.
The lack of a significant difference in the incidence of
recurrent coronary events between patients with silent isch-
emia and those with no inducible ischemia during noninvasive
testing is contrary to the findings of several previous investi-
gations (30,31) performed in the immediate postinfarction
period. It should be reemphasized that the current study was
carried out in a cohort of patients who had clinically stable
coronary disease (low to moderate risk) at the time of enroll-
ment, several months after the acute index coronary event. Our
results do not necessarily imply that aggressive therapy to
eliminate silent ischemia in higher risk patient populations
may not carry some prognostic benefit. However, they do
suggest that treatment of silent ischemia in lower risk popula-
tions has less potential for benefit (32).
Conclusions. We found that patients with stable coronary
disease who experienced silent myocardial ischemia during
noninvasive stress testing 1 to 6 months after a coronary event
had less severe and extensive myocardial ischemia than those
with symptomatic ischemia. Relative to those who experienced
symptomatic ischemia, patients who developed silent ischemia
also had a significantly decreased risk of subsequent cardiac
events and cardiac death. Cox regression analysis demon-
strated that the presence or absence of angina during testing
was related to outcome in an independent manner. Hence, in
clinically stable patients with exercise-induced ischemia, it
appears that the additional presence of anginal symptoms
during exercise tends to identify those with a greater amount of
jeopardized myocardium who are at increased risk for an
adverse outcome.
We are indebted to Moonseong Heo, PhD and Patricia Severski for assistance
with the statistical analysis.
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